

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ELAN PHARMACEUTICALS, INC.	07/26/2012
RECEIVING PARTY DATA	
Name:	NEOTOPE BIOSCIENCES LIMITED
Street Address:	Lower Grand Canal Street
Internal Address:	Treasury Building
City:	Dublin
State/Country:	IRELAND
Postal Code:	2
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13032412
CORRESPONDENCE DATA	
Fax Number:	4048887490
Phone:	404.888.7423
Email:	RTimm@wcsr.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Womble Carlyle Sandridge & Rice, LLP
Address Line 1:	P.O. Box 7037
Address Line 4:	Atlanta, GEORGIA 30357-0037
ATTORNEY DOCKET NUMBER:	63413.0039.6
NAME OF SUBMITTER:	Russell S. Timm, Ph.D.
Total Attachments: 3 source=13_032412_from_EPI_to_Neotope#page1.tif source=13_032412_from_EPI_to_Neotope#page2.tif source=13_032412_from_EPI_to_Neotope#page3.tif	

CH \$40.00 13032412

PATENT

## ASSIGNMENT

THIS ASSIGNMENT, by ELAN PHARMACEUTICALS, INC., a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 180 Oyster Point Boulevard, South San Francisco, CA 94080 (hereinafter referred to as "Assignor"), witnesseth:

WHEREAS, Assignor is the owner of the entire right, title and interest in and to the invention set forth as follows:

Title of Invention: Chimeric, Humanized, or Human Antibody 2A4

US Application No.: 13/032,412

Filing Date: February 22, 2011

WHEREAS, NEOTOPE BIOSCIENCES LIMITED, a private limited company incorporated under the laws of Ireland, and having its registered office at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (hereinafter referred to as "Assignee"), pursuant to the Research and Development Agreement dated as of March 23, 2010 (hereinafter referred to as "the R&D Agreement") between Assignor and Assignee, has acquired Assignor's right, title, and interest in and to the above-mentioned application and invention, the right to file applications on said invention, and the right, title and interest in and to any applications, including provisional applications, on said invention for Letters Patent of the United States or other countries, and any applications claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, pursuant to the R&D Agreement, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has assigned, transferred, and set over, and by these presents does assign, transfer, and set over unto Assignee, and Assignee's successors, legal representatives, and assigns, all of Assignor's right, title, and interest in and to the above-mentioned invention and application, the right to file applications on said invention and the right, title and interest in and to any such applications, including provisional applications, and any applications claiming priority from said applications for Letters Patent of the United States or other countries, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the Paris Convention for the Protection of Industrial Property, including the right to claim priority, the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by Assignor had its assignment not been made;

AND Assignor hereby covenants that Assignor has the full right to convey the interest assigned by this Assignment, and Assignor has not executed and will not execute any agreement in conflict with this Assignment;

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives, and assigns, that Assignor shall, whenever counsel of Assignee, or the counsel of its successors, legal representatives, and assigns, advises that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said invention in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said applications, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention, without charge to Assignee, but at the cost and expense of Assignee, its successors, legal representatives, and assigns;


AND Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to Assignee as the assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of Assignee, its successors, legal representatives, and assigns;

AND the undersigned hereby grant(s) an authorized representative of Assignee the power to insert in this Assignment the application number and filing date and any further identification that may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

IN TESTIMONY WHEREOF, a duly authorized representative of Assignor has signed on the date indicated.

ELAN PHARMACEUTICALS, INC.

Date: 7/26/12

By: 

Printed Name: Atulya R. Agarwal

Title: Chief Intellectual Property Officer

EXECUTE IN THE PRESENCE OF A NOTARY

# CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

CIVIL CODE § 1189


State of California

County of SAN MATEO

On July 26, 2012 before me, Sushma Sanganeria-Brady, Notary Public  
Date Here Insert Name and Title of the Officer

personally appeared ATULYA AGARWAL  
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: Sushma Sanganeria-Brady  
Signature of Notary Public

Place Notary Seal Above

## OPTIONAL

*Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.*

### Description of Attached Document

Title or Type of Document: 589-48-CNT(6)

Document Date: \_\_\_\_\_ Number of Pages: \_\_\_\_\_

Signer(s) Other Than Named Above: \_\_\_\_\_

### Capacity(ies) Claimed by Signer(s)

Signer's Name: \_\_\_\_\_ Signer's Name: \_\_\_\_\_

☐ Corporate Officer — Title(s): \_\_\_\_\_ ☐ Corporate Officer — Title(s): \_\_\_\_\_

☐ Individual ☐ Individual

☐ Partner — ☐ Limited ☐ General ☐ Partner — ☐ Limited ☐ General

☐ Attorney in Fact ☐ Attorney in Fact

☐ Trustee ☐ Trustee

☐ Guardian or Conservator ☐ Guardian or Conservator

☐ Other: \_\_\_\_\_ ☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_ Signer Is Representing: \_\_\_\_\_